Skip to main content

Main menu

  • Home
  • Issues
    • Issue in progress
    • Issues by date
  • Sections
    • Editorial
    • Review
    • Research
    • Commentary
    • Psychopharmacology for the Clinician
    • Letters to the Editor
  • Topic Collections
  • Instructions for Authors
    • Overview for authors
    • Submission checklist
    • Editorial policies
    • Publication fees
    • Submit a manuscript
    • Dr. Francis Wayne Quan Memorial Prize
    • Open access
  • Alerts
    • Email alerts
    • RSS
  • About
    • General information
    • Staff
    • Editorial Board
    • Contact
  • CMAJ JOURNALS
    • CMAJ
    • CMAJ Open
    • CJS
    • JAMC

User menu

Search

  • Advanced search
JPN
  • CMAJ JOURNALS
    • CMAJ
    • CMAJ Open
    • CJS
    • JAMC
JPN

Advanced Search

  • Home
  • Issues
    • Issue in progress
    • Issues by date
  • Sections
    • Editorial
    • Review
    • Research
    • Commentary
    • Psychopharmacology for the Clinician
    • Letters to the Editor
  • Topic Collections
  • Instructions for Authors
    • Overview for authors
    • Submission checklist
    • Editorial policies
    • Publication fees
    • Submit a manuscript
    • Dr. Francis Wayne Quan Memorial Prize
    • Open access
  • Alerts
    • Email alerts
    • RSS
  • About
    • General information
    • Staff
    • Editorial Board
    • Contact
  • Subscribe to our alerts
  • RSS feeds
  • Follow JPN on Twitter
Research Paper
Open Access

Effect of short-term, high-dose probiotic supplementation on cognition, related brain functions and BDNF in patients with depression: a secondary analysis of a randomized controlled trial

Else Schneider, Jessica P.K. Doll, Nina Schweinfurth, Cedric Kettelhack, Anna-Chiara Schaub, Gulnara Yamanbaeva, Nimmy Varghese, Laura Mählmann, Serge Brand, Anne Eckert, Stefan Borgwardt, Undine E. Lang and André Schmidt
J Psychiatry Neurosci January 18, 2023 48 (1) E23-E33; DOI: https://doi.org/10.1503/jpn.220117
Else Schneider
From the University of Basel, Department of Psychiatry (UPK), Basel, Switzerland (Schneider, Doll, Schweinfurth, Kettelhack, Schaub, Yamanbaeva, Varghese, Mählmann, Brand, Eckert, Borgwardt, Lang, Schmidt); the Transfaculty Research Platform Molecular and Cognitive Neuroscience, University of Basel, Basel, Switzerland (Varghese, Eckert); the Sleep Disorders Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran (Brand); the Substance Abuse Prevention Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran (Brand); the Department of Sport, Exercise and Health, Division of Sport Science and Psychosocial Health, University of Basel, Basel, Switzerland (Brand); the School of Medicine, Tehran University of Medical Sciences, Tehran, Iran (Brand); the Department of Research, St. Clara Hospital, Basel, Switzerland ([CE; authors were not indicated for this affiliation]}; the Department of Psychiatry and Psychotherapy, University of Lübeck, Lübeck, Germany (Borgwardt)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jessica P.K. Doll
From the University of Basel, Department of Psychiatry (UPK), Basel, Switzerland (Schneider, Doll, Schweinfurth, Kettelhack, Schaub, Yamanbaeva, Varghese, Mählmann, Brand, Eckert, Borgwardt, Lang, Schmidt); the Transfaculty Research Platform Molecular and Cognitive Neuroscience, University of Basel, Basel, Switzerland (Varghese, Eckert); the Sleep Disorders Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran (Brand); the Substance Abuse Prevention Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran (Brand); the Department of Sport, Exercise and Health, Division of Sport Science and Psychosocial Health, University of Basel, Basel, Switzerland (Brand); the School of Medicine, Tehran University of Medical Sciences, Tehran, Iran (Brand); the Department of Research, St. Clara Hospital, Basel, Switzerland ([CE; authors were not indicated for this affiliation]}; the Department of Psychiatry and Psychotherapy, University of Lübeck, Lübeck, Germany (Borgwardt)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nina Schweinfurth
From the University of Basel, Department of Psychiatry (UPK), Basel, Switzerland (Schneider, Doll, Schweinfurth, Kettelhack, Schaub, Yamanbaeva, Varghese, Mählmann, Brand, Eckert, Borgwardt, Lang, Schmidt); the Transfaculty Research Platform Molecular and Cognitive Neuroscience, University of Basel, Basel, Switzerland (Varghese, Eckert); the Sleep Disorders Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran (Brand); the Substance Abuse Prevention Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran (Brand); the Department of Sport, Exercise and Health, Division of Sport Science and Psychosocial Health, University of Basel, Basel, Switzerland (Brand); the School of Medicine, Tehran University of Medical Sciences, Tehran, Iran (Brand); the Department of Research, St. Clara Hospital, Basel, Switzerland ([CE; authors were not indicated for this affiliation]}; the Department of Psychiatry and Psychotherapy, University of Lübeck, Lübeck, Germany (Borgwardt)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cedric Kettelhack
From the University of Basel, Department of Psychiatry (UPK), Basel, Switzerland (Schneider, Doll, Schweinfurth, Kettelhack, Schaub, Yamanbaeva, Varghese, Mählmann, Brand, Eckert, Borgwardt, Lang, Schmidt); the Transfaculty Research Platform Molecular and Cognitive Neuroscience, University of Basel, Basel, Switzerland (Varghese, Eckert); the Sleep Disorders Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran (Brand); the Substance Abuse Prevention Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran (Brand); the Department of Sport, Exercise and Health, Division of Sport Science and Psychosocial Health, University of Basel, Basel, Switzerland (Brand); the School of Medicine, Tehran University of Medical Sciences, Tehran, Iran (Brand); the Department of Research, St. Clara Hospital, Basel, Switzerland ([CE; authors were not indicated for this affiliation]}; the Department of Psychiatry and Psychotherapy, University of Lübeck, Lübeck, Germany (Borgwardt)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna-Chiara Schaub
From the University of Basel, Department of Psychiatry (UPK), Basel, Switzerland (Schneider, Doll, Schweinfurth, Kettelhack, Schaub, Yamanbaeva, Varghese, Mählmann, Brand, Eckert, Borgwardt, Lang, Schmidt); the Transfaculty Research Platform Molecular and Cognitive Neuroscience, University of Basel, Basel, Switzerland (Varghese, Eckert); the Sleep Disorders Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran (Brand); the Substance Abuse Prevention Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran (Brand); the Department of Sport, Exercise and Health, Division of Sport Science and Psychosocial Health, University of Basel, Basel, Switzerland (Brand); the School of Medicine, Tehran University of Medical Sciences, Tehran, Iran (Brand); the Department of Research, St. Clara Hospital, Basel, Switzerland ([CE; authors were not indicated for this affiliation]}; the Department of Psychiatry and Psychotherapy, University of Lübeck, Lübeck, Germany (Borgwardt)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gulnara Yamanbaeva
From the University of Basel, Department of Psychiatry (UPK), Basel, Switzerland (Schneider, Doll, Schweinfurth, Kettelhack, Schaub, Yamanbaeva, Varghese, Mählmann, Brand, Eckert, Borgwardt, Lang, Schmidt); the Transfaculty Research Platform Molecular and Cognitive Neuroscience, University of Basel, Basel, Switzerland (Varghese, Eckert); the Sleep Disorders Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran (Brand); the Substance Abuse Prevention Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran (Brand); the Department of Sport, Exercise and Health, Division of Sport Science and Psychosocial Health, University of Basel, Basel, Switzerland (Brand); the School of Medicine, Tehran University of Medical Sciences, Tehran, Iran (Brand); the Department of Research, St. Clara Hospital, Basel, Switzerland ([CE; authors were not indicated for this affiliation]}; the Department of Psychiatry and Psychotherapy, University of Lübeck, Lübeck, Germany (Borgwardt)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nimmy Varghese
From the University of Basel, Department of Psychiatry (UPK), Basel, Switzerland (Schneider, Doll, Schweinfurth, Kettelhack, Schaub, Yamanbaeva, Varghese, Mählmann, Brand, Eckert, Borgwardt, Lang, Schmidt); the Transfaculty Research Platform Molecular and Cognitive Neuroscience, University of Basel, Basel, Switzerland (Varghese, Eckert); the Sleep Disorders Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran (Brand); the Substance Abuse Prevention Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran (Brand); the Department of Sport, Exercise and Health, Division of Sport Science and Psychosocial Health, University of Basel, Basel, Switzerland (Brand); the School of Medicine, Tehran University of Medical Sciences, Tehran, Iran (Brand); the Department of Research, St. Clara Hospital, Basel, Switzerland ([CE; authors were not indicated for this affiliation]}; the Department of Psychiatry and Psychotherapy, University of Lübeck, Lübeck, Germany (Borgwardt)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laura Mählmann
From the University of Basel, Department of Psychiatry (UPK), Basel, Switzerland (Schneider, Doll, Schweinfurth, Kettelhack, Schaub, Yamanbaeva, Varghese, Mählmann, Brand, Eckert, Borgwardt, Lang, Schmidt); the Transfaculty Research Platform Molecular and Cognitive Neuroscience, University of Basel, Basel, Switzerland (Varghese, Eckert); the Sleep Disorders Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran (Brand); the Substance Abuse Prevention Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran (Brand); the Department of Sport, Exercise and Health, Division of Sport Science and Psychosocial Health, University of Basel, Basel, Switzerland (Brand); the School of Medicine, Tehran University of Medical Sciences, Tehran, Iran (Brand); the Department of Research, St. Clara Hospital, Basel, Switzerland ([CE; authors were not indicated for this affiliation]}; the Department of Psychiatry and Psychotherapy, University of Lübeck, Lübeck, Germany (Borgwardt)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Serge Brand
From the University of Basel, Department of Psychiatry (UPK), Basel, Switzerland (Schneider, Doll, Schweinfurth, Kettelhack, Schaub, Yamanbaeva, Varghese, Mählmann, Brand, Eckert, Borgwardt, Lang, Schmidt); the Transfaculty Research Platform Molecular and Cognitive Neuroscience, University of Basel, Basel, Switzerland (Varghese, Eckert); the Sleep Disorders Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran (Brand); the Substance Abuse Prevention Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran (Brand); the Department of Sport, Exercise and Health, Division of Sport Science and Psychosocial Health, University of Basel, Basel, Switzerland (Brand); the School of Medicine, Tehran University of Medical Sciences, Tehran, Iran (Brand); the Department of Research, St. Clara Hospital, Basel, Switzerland ([CE; authors were not indicated for this affiliation]}; the Department of Psychiatry and Psychotherapy, University of Lübeck, Lübeck, Germany (Borgwardt)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne Eckert
From the University of Basel, Department of Psychiatry (UPK), Basel, Switzerland (Schneider, Doll, Schweinfurth, Kettelhack, Schaub, Yamanbaeva, Varghese, Mählmann, Brand, Eckert, Borgwardt, Lang, Schmidt); the Transfaculty Research Platform Molecular and Cognitive Neuroscience, University of Basel, Basel, Switzerland (Varghese, Eckert); the Sleep Disorders Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran (Brand); the Substance Abuse Prevention Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran (Brand); the Department of Sport, Exercise and Health, Division of Sport Science and Psychosocial Health, University of Basel, Basel, Switzerland (Brand); the School of Medicine, Tehran University of Medical Sciences, Tehran, Iran (Brand); the Department of Research, St. Clara Hospital, Basel, Switzerland ([CE; authors were not indicated for this affiliation]}; the Department of Psychiatry and Psychotherapy, University of Lübeck, Lübeck, Germany (Borgwardt)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stefan Borgwardt
From the University of Basel, Department of Psychiatry (UPK), Basel, Switzerland (Schneider, Doll, Schweinfurth, Kettelhack, Schaub, Yamanbaeva, Varghese, Mählmann, Brand, Eckert, Borgwardt, Lang, Schmidt); the Transfaculty Research Platform Molecular and Cognitive Neuroscience, University of Basel, Basel, Switzerland (Varghese, Eckert); the Sleep Disorders Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran (Brand); the Substance Abuse Prevention Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran (Brand); the Department of Sport, Exercise and Health, Division of Sport Science and Psychosocial Health, University of Basel, Basel, Switzerland (Brand); the School of Medicine, Tehran University of Medical Sciences, Tehran, Iran (Brand); the Department of Research, St. Clara Hospital, Basel, Switzerland ([CE; authors were not indicated for this affiliation]}; the Department of Psychiatry and Psychotherapy, University of Lübeck, Lübeck, Germany (Borgwardt)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Undine E. Lang
From the University of Basel, Department of Psychiatry (UPK), Basel, Switzerland (Schneider, Doll, Schweinfurth, Kettelhack, Schaub, Yamanbaeva, Varghese, Mählmann, Brand, Eckert, Borgwardt, Lang, Schmidt); the Transfaculty Research Platform Molecular and Cognitive Neuroscience, University of Basel, Basel, Switzerland (Varghese, Eckert); the Sleep Disorders Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran (Brand); the Substance Abuse Prevention Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran (Brand); the Department of Sport, Exercise and Health, Division of Sport Science and Psychosocial Health, University of Basel, Basel, Switzerland (Brand); the School of Medicine, Tehran University of Medical Sciences, Tehran, Iran (Brand); the Department of Research, St. Clara Hospital, Basel, Switzerland ([CE; authors were not indicated for this affiliation]}; the Department of Psychiatry and Psychotherapy, University of Lübeck, Lübeck, Germany (Borgwardt)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
André Schmidt
From the University of Basel, Department of Psychiatry (UPK), Basel, Switzerland (Schneider, Doll, Schweinfurth, Kettelhack, Schaub, Yamanbaeva, Varghese, Mählmann, Brand, Eckert, Borgwardt, Lang, Schmidt); the Transfaculty Research Platform Molecular and Cognitive Neuroscience, University of Basel, Basel, Switzerland (Varghese, Eckert); the Sleep Disorders Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran (Brand); the Substance Abuse Prevention Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran (Brand); the Department of Sport, Exercise and Health, Division of Sport Science and Psychosocial Health, University of Basel, Basel, Switzerland (Brand); the School of Medicine, Tehran University of Medical Sciences, Tehran, Iran (Brand); the Department of Research, St. Clara Hospital, Basel, Switzerland ([CE; authors were not indicated for this affiliation]}; the Department of Psychiatry and Psychotherapy, University of Lübeck, Lübeck, Germany (Borgwardt)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Responses
  • Metrics
  • PDF
Loading

Article Figures & Tables

Figures

  • Tables
  • Figure 1
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1

    (A) Change scores from baseline to post-intervention per group for immediate recall in the VLMT (probiotics: n = 17, placebo: n = 23). (B) Mean trajectory of immediate recall in the VLMT per group from baseline to post-intervention (week 4) and follow-up assessment (week 8). Numbers of participants per time point and per group were as follows: baseline probiotics: n = 19; baseline placebo: n = 24; post-intervention probiotics: n = 17; post-intervention placebo: n = 23; follow-up probiotics: n = 15; follow-up placebo: n = 23. VLMT = Verbal Learning Memory Test.

  • Figure 2
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2

    Pattern of activation change from baseline to post-intervention per group and condition based on the hippocampal cluster revealed in the group contrast (probiotics group > placebo group) for the 0-back task (probiotics: n = 14; placebo: n = 18). Probiotics group v. placebo group

  • Figure 3
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3

    (A) Correlation between left hippocampal activation changes and RT differences in the 1-back condition. (B) Correlation between the left hippocampal activation changes and RT differences in the 2-back condition (probiotics: n = 14; placebo: n = 18). RT = reaction time.

Tables

  • Figures
    • View popup
    Table 1

    Brief descriptions of the cognitive tasks used

    Cognitive testDescriptionCognitive domainOutcomeMeasure
    Verbal Learning Memory TestA list of 15 nouns is read to the participant and then recalled by the participant after each learning trial (5 times, Dg1–Dg5). Then an interference list of 15 nouns is read out to and recalled by the participant. The original list is recalled immediately after the interference list (Dg6) and 20–30mins after the interference list (Dg7).Verbal learning and memoryImmediate recall∑ Dg1–Dg5
    Intermediate recallDg5–Dg6
    Long-term recallDg5–Dg7
    Corsi block tapping testThe clinician indicated a sequence by tapping on blocks in a specific order, beginning with 2 blocks, successively adding more blocks to the sequence. In the forward condition, the participants repeat the sequence after the clinician. In the backward condition, the participants repeat the sequence, but start with the last block.Visual-spatial short-term memory and working memoryCorsi block forwardNumber of correct sequences forward
    Corsi block backwardNumber of correct sequences backward
    Trail Making TestThe participant connects a series of numbers (TMT A) or numbers and letters (TMT B) in the right order as fast as possible without lifting the pen.Attention and executive functioningTMT ASeconds needed for task completion
    TMT B
    2-back taskParticipants are presented with a sequence of letters and have to indicate when the current letters match the one from N-steps earlier in the sequence. The 2-back task consists of 3 different conditions with N = 0, N = 1, and N = 2.Working memoryReaction time differenceMean reaction time for correct answers (in seconds)
    AccuracyCorrectly given answers/number
    • TMT = Trail Making Test; VLMT = Verbal Learning Memory Test.

    • View popup
    Table 2

    Demographic and clinical characteristics of both study groups at baseline

    CharacteristicRandomized sample
    n = 60
    CCA* sample
    n = 47
    Modified ITT† sample
    n = 43
    Probiotic
    n = 30
    Placebo
    n = 30
    Group comparisonProbiotic
    n = 21
    Placebo
    n = 26
    Group comparisonProbiotic
    n = 19
    Placebo
    n = 24
    Group comparison
    Sex, female, n (%)20 (66.7)16 (53.33)χ21 = 0.63, p = 0.4314 (67)13 (50)χ21 = 0.73, p = 0.4914 (74)12 (50)χ21 = 1.60, p = 0.21
    Age, mean ± SD38.03 ± 11.3237.87 ± 10.32W = 443, p = 0.9239.43 ± 11.4538.77 ± 10.32W = 278, p = 0.9239.21 ± 11.5338.04 ± 10.24W = 238.5, p = 0.81
    BMI, mean ± SD23.53 ± 3.8225.20 ± 3.50W = 334, p = 0.1323.50 ± 3.6724.88 ± 3.95W = 207, p = 0.2323.83 ± 3.6625.13 ± 4.01W = 177, p = 0.30
    Smoking, n (%)
     ≥ 1/day9 (30)12 (40)χ24 = 3.21, p = 0.527 (33)11 (42)χ21 = 0.27, p = 0.605 (26)10 (42)χ21 = 0.87, p = 0.35
     NA10 (33.3)8 (26.7)3 (14)5 (19)3 (16)5 (21)
    Hospitalization, n (%)
     110 (33)13 (43)W = 274, p = 0.418 (38)12 (46)W = 224.5, p = 0.457 (37)12 (50)W = 210.5, p = 0.32
     24 (13)5 (17)4 (19)5 (19)4 (21)4 (17)
     33 (10)3 (10)3 (14)3 (12)3 (16)3 (13)
     40 (0)1 (3)0 (0)1 (4)0 (0)1 (4)
     53 (10)0 (0)3 (14)0 (0)3 (16)0 (0)
     ≥ 61 (3)1 (3)0 (0)1 (4)0 (0)1 (4)
     NA9 (30)7 (23)3 (14)4 (15)2 (11)3 (13)
    Education, n (%)
     Primary9 (30)6 (20)W = 423, p = 0.427 (33)4 (15)W = 269.5, p = 0.886 (32)4 (17)W = 237, p = 0.63
     Secondary3 (10)12 (40)3 (14)12 (46)3 (16)12 (50)
     Tertiary16 (53)9 (30)11 (52)9 (35)10 (53)7 (29)
     NA2 (7)3 (10)0 (0)1 (4)0 (0)0 (0)
    Medication, DDD, mean ± SD
     Antidepressant equivalentsNANANA1.73 ± 1.301.79 ± 1.09W = 253, p = 0.681.86 ± 1.301.82 ± 1.12W = 227, p = 0.99
     Antipsychotics equivalentsNANANA0.30 ± 0.680.22 ± 0.30W = 278, p = 0.920.33 ± 0.710.24 ± 0.31W = 241, p = 0.76
    Clinical measures, mean ± SD
     HAM-D18.90 ± 4.716.7 ± 4.10W = 552, p = 0.0818.93 ± 4.7816.5 ± 4.04W = 363, p = 0.0519.13 ± 4.8916.5 ± 4.18W = 311, p = 0.04
     BDI22.5 ± 8.1022.12 ± 9.90W = 461.5, p = 0.6922.38 ± 7.5422.33 ± 10.17W = 257.5, p = 0.9621.53 ± 7.5922.31 ± 9.94W = 218.5, p = 0.96
     STAI142.32 ± 5.52541.10 ± 6.53W = 472.5, p = 0.4249.75 ± 13.8952.36 ± 10.40W = 229.5, p = 0.6549 ± 14.1151.83 ± 10.61W = 191, p = 0.68
     GSRS‡30.21 ± 9.9429.53 ± 12.06W = 479, p = 0.5128.52 ± 9.4829.83 ± 12.45W = 261, p = 0.9828.16 ± 9.6529.96 ± 12.79W = 211.5, p = 0.87
    Compliance, %, mean ± SDNANANA83 ± 17.2186 ± 11.72W = 231, p = 0.7687 ± 8.4488 ± 8.17W = 186, p = 0.84
    • BDI = Beck Depression Inventory; BMI = body mass index; CCA = complete case analysis; DDD = defined daily dose; GSRS = Gastrointestinal Symptom Rating Scale; HAM-D = Hamilton Rating Scale for Depression; ITT = intention to treat; NA = not applicable; SD = standard deviation; STAI1 = State–Trait Anxiety Inventory 1.

    • ↵* Referred to as ITT in Schaub et al.19

    • ↵† Also referred to as modified ITT in Schaub et al.19

    • ↵‡ Non-normally distributed, b square root–transformed.

    • View popup
    Table 3

    Results of cognitive measurements

    TestMeasureCS* baseline to post-interventionRandom intercept modelCorrelation with BDNF (including age)
    Verbal Learning Memory TestImmediate recall (Dg1–5)t37.86 = −2.16, p = 0.037F2, 76.12 = 2.55, p = 0.084Probiotics: r = 0.26, p = 0.33
    Placebo: r = −0.01, p = 0.97
    Intermediate recall (Dg5–Dg6)t37.24 = 0.24, p = 0.82F2, 68.32 = 1.29, p = 0.28Probiotics: r = 0.04, p = 0.88
    Placebo: r = −0.05, p = 0.86
    Long-term recall (Dg5–Dg7)t35.47 = −1.79, p = 0.082F2, 77.57 = 1.74, p = 0.18Probiotics: r = 0.10, p = 0.72
    Placebo: r = 0.18, p = 0.52
    Corsi block tapping testCorrect sequence forwardt35.15 = −0.55, p = 0.59F2, 79.51 = 0.09, p = 0.91–
    Correct sequence backwardt37.08 = −1.43, p = 0.16F2, 79.92 = 1.44, p = 0.24–
    Trail Making TestTMT A timet29.95 = 0.081, p = 0.94F2, 71.57 = 0.06, p = 0.94–
    TMT B timet28.44 = −1.68, p = 0.10F2, 70.92 = 1.02, p = 0.36–
    2-back taskReaction timet26.97 = 1.037, p = 0.31–Probiotics: r = −0.29, p = 0.34
    Placebo: = 0.50, p = 0.08
    Accuracyt22.20 = 0.098, p = 0.92–Probiotics: r = −0.44, p = 0.13
    Placebo: r = 0.19, p = 0.53
    • BDNF = brain-derived neurotrophic factor; CS = Change Score; TMT = Trail Making Test.

    • ↵* Calculated by subtracting the post-intervention score from the baseline score.

PreviousNext
Back to top

In this issue

Journal of Psychiatry and Neuroscience: 48 (1)
J Psychiatry Neurosci
Vol. 48, Issue 1
18 Jan 2023
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on JPN.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Effect of short-term, high-dose probiotic supplementation on cognition, related brain functions and BDNF in patients with depression: a secondary analysis of a randomized controlled trial
(Your Name) has sent you a message from JPN
(Your Name) thought you would like to see the JPN web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Effect of short-term, high-dose probiotic supplementation on cognition, related brain functions and BDNF in patients with depression: a secondary analysis of a randomized controlled trial
Else Schneider, Jessica P.K. Doll, Nina Schweinfurth, Cedric Kettelhack, Anna-Chiara Schaub, Gulnara Yamanbaeva, Nimmy Varghese, Laura Mählmann, Serge Brand, Anne Eckert, Stefan Borgwardt, Undine E. Lang, André Schmidt
J Psychiatry Neurosci Jan 2023, 48 (1) E23-E33; DOI: 10.1503/jpn.220117

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Effect of short-term, high-dose probiotic supplementation on cognition, related brain functions and BDNF in patients with depression: a secondary analysis of a randomized controlled trial
Else Schneider, Jessica P.K. Doll, Nina Schweinfurth, Cedric Kettelhack, Anna-Chiara Schaub, Gulnara Yamanbaeva, Nimmy Varghese, Laura Mählmann, Serge Brand, Anne Eckert, Stefan Borgwardt, Undine E. Lang, André Schmidt
J Psychiatry Neurosci Jan 2023, 48 (1) E23-E33; DOI: 10.1503/jpn.220117
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

Similar Articles

Content

  • Current issue
  • Past issues
  • Collections
  • Alerts
  • RSS

Authors & Reviewers

  • Overview for Authors
  • Submit a manuscript
  • Manuscript Submission Checklist

About

  • General Information
  • Staff
  • Editorial Board
  • Contact Us
  • Advertising
  • Reprints
  • Copyright and Permissions
  • Accessibility
  • CMA Civility Standards
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1180-4882.

All editorial matter in JPN represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.
To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: [email protected].
View CMA's Accessibility policy.

Powered by HighWire